Prognosis of mesothelioma patients is poor, and peritoneal mesothelioma patients are no exception. Most peritoneal mesothelioma treatment regimens for patients include palliative methods such as mesothelioma chemotherapy and radiation therapy. However, if the disease is diagnosed in its earlier stages, such patients as those diagnosed with stage 1 mesothelioma, these individuals  may be eligible for surgical resection of the disease, which could potentially add years to initial prognoses.

Surgery is possible for patients diagnosed with earlier-stage disease. Some surgical options include pneumonectomy, extra-pleural pneumonectomy, and palliative procedures such as thoracentesis or pleurodesis. Pneumonectomy and extra-pleural pneumonectomy are extensive procedures that involve there removal of the affect lung and surrounding body structures. Certain physicians, including Dr. David Sugarbaker of the International Mesothelioma Program at Brigham and Women’s Hospital in Boston, MA, have become extremely well-versed and experienced in the surgical treatment of malignant mesothelioma. In many cases, surgical treatments for mesothelioma will be coupled with chemotherapy or radiation therapy regimens.

Chemotherapy is the most common treatment for mesothelioma disease. Currently, there is only a single chemotherapy regimen (Alimta (pemetrexed) in conjunction with Cisplatin) approved by the Food and Drug Administration as a prescribed therapy for the treatment of malignant pleural mesothelioma. There are however, dozens of clinical trials being conducted for mesothelioma patients experimenting with new drugs, including gemcitabine, Navelbine, Onconase, and others for the treatment of malignant peritoneal mesothelioma.